MONTREAL, QUEBEC--(Marketwire - June 22, 2009) - Adaltis Inc. (TSX: ADS), an international in vitro diagnostic (IVD) company, today announced that it has secured an additional bridge loan of up to $2 million from Victoria Square Ventures Inc. and has issued this day a promissory note in the aggregate principal amount of $750,000 to Victoria Square Ventures Inc. in respect of the first tranche. Additional advances under the facility are at the sole option of the lender. The promissory note issued today is secured by certain assets of Adaltis, has a 60-day term and bears interest at an annual rate of 16%. The note is not convertible into securities of Adaltis.
As previously disclosed, Adaltis is still pursuing discussions with certain parties to provide additional longer term financing in order to ensure continuing operations beyond June 2009. No definitive agreements with potential investors have been reached yet and there can be no assurance that such agreements will be reached.
There can be no assurance that any transaction will be concluded or that Adaltis will be able to continue as a going concern without successfully raising additional financing through borrowings, share issuances, sale of assets or otherwise. The outcome of these matters is in large part beyond the Corporation's control and will likely be subject to a number of conditions, some of which may not be favourable to the Corporation.
The issuance of the promissory note to Victoria Square Ventures Inc. may be considered a related party transaction within applicable securities legislation. As such, this news release could not be issued more than 21 days before the issuance of the note as the Corporation had urgent liquidity needs.
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of applicable Canadian securities legislation. These statements include those relating to statements that are not historical facts, and reflect the current intentions, plans, expectations and beliefs of Adaltis' management. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors outside of management's control. A number of factors could cause actual results of Adaltis to differ materially from the results predicted in the forward-looking statements, including, but not limited to, risks associated with obtaining regulatory registrations, affecting our ability to achieve our strategy in China and other emerging markets, the successful and timely completion of our ongoing research and development efforts in particular related to EclecticaTM, the launch of new products, the uncertainties of market factors and regulatory processes to which our business is subject, the ability to recover the value of our holdings of asset-backed commercial paper following the restructuring of the asset-backed commercial paper market, and the availability and terms of any financing. For additional information with respect to certain of these and other factors, refer to our Annual Information Form under the heading "Risk Factors" filed with the Canadian securities commissions.
The forward-looking statements contained in this news release represent the expectations of Adaltis and its subsidiaries as at the date hereof and accordingly are subject to change after such date. However, Adaltis and its subsidiaries expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
About Adaltis Inc.
Adaltis is an international in vitro diagnostic company with a mission to become a leading provider of in vitro diagnostic products in emerging markets, with a particular focus on China.
With the strategic advantage of its "state of the art" reagent manufacturing facility located in Shanghai, China, a complete IVD product offering targeting emerging markets, and a strong international sales and distribution platform, Adaltis is able to manufacture high-quality products in a low-cost GMP environment, in order to service existing markets in Europe, while providing a platform to penetrate the high-growth Chinese in vitro diagnostic market.
Adaltis is headquartered in Montreal, with offices in China, Italy, Mexico and other parts of the world.